Cancer Chemotherapy and Pharmacology

, Volume 71, Issue 2, pp 399–404 | Cite as

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma

  • Cormac Owens
  • Valerie Laurence
  • Lofti Benboubker
  • Anne-Sophie Defachelles
  • Didier Cupissol
  • Hervé Rubie
  • Hervé Brisse
  • Annie Rey
  • Liliane Ollivier
  • Dominique Couanet
  • Christiane Baunin
  • Céline Mahier Aït-Oukhatar
  • Odile Oberlin
Original Article



Phase II trials demonstrate the activity of cisplatin in patients with refractory Ewing sarcoma family tumours (ESFT) and also the feasibility of giving cisplatin with oral VP16 in a variety of different cancers. This trial was conducted to evaluate the activity and toxicity profile of this combination delivered as outpatient therapy in patients with refractory/relapsed ESFT.


Cisplatin was administered on days 1, 8 and 15 and days 29, 36 and 43 (70 mg/m2/dose for patients <21 years of age and 50 mg/m2/dose ≥21 years). VP16 was administered at a dose of 50 mg/m2 on days 1–15 and days 29–43 inclusive. A three-stage Fleming statistical design was used for analysis.


Between January 2003 and October 2006, 45 patients aged between 5 and 46 years (median 19) were enrolled. Thirty-eight were evaluable for response. Patients had previously received one to three lines of chemotherapy (median = one). Seventy-three per cent of the patients had grade 3/4 neutropenia, 20 % developed fever, 40 % had grade 3/4 anaemia, 68 % grade 3/4 thrombocytopenia and 16 % grade 2/3 ototoxicity. Measured response after 2 cycles: 0 CR, 7 PR (18 %), 13 SD (34 %), 18 PD (48 %). There was excellent concordance between unidimensional and bidimensional criteria in 31 of 33 responses (94 %). PFS at 1 year was 39 %, with a median PFS of 6 months. Overall survival at 1 year was 44 %; median survival was 11 months.


Cisplatin combined with oral VP16 is well tolerated and has acceptable side effects, but limited clinical activity in refractory/relapsed ESFT.


Ewing sarcoma Relapse Paediatric Phase II trial Cisplatin VP-16 


  1. 1.
    Kolb EA, Kushner BH, Gorlick R et al (2003) Long-term event-free survival after intensive chemotherapy in Ewing’s family of tumors in children and young adults. J Clin Oncol 21(18):3423–3430PubMedCrossRefGoogle Scholar
  2. 2.
    Paulussen M, Craft AW, Lewis I et al (2008) Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared to ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 26(27):4385–4393PubMedCrossRefGoogle Scholar
  3. 3.
    Rodrigues-Galindo C, Spunt SL, Pappo AS (2003) Treatment of Ewing sarcoma family of tumours: current status and outlook for the future. Med Pediatr Oncol 40:276–287CrossRefGoogle Scholar
  4. 4.
    Cotterill SJ, Ahrens S, Paulussen M et al (2000) Prognostic factors in Ewing’s tumour of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114PubMedGoogle Scholar
  5. 5.
    Bacci G, Ferrari S, Longhi A et al (2003) Therapy and survival after recurrence of Ewing’s tumors. The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14:1654–1659PubMedCrossRefGoogle Scholar
  6. 6.
    Barker LM, Pendergrass TW, Sanders JE, Hawkins DS (2005) Survival after recurrence of Ewing tumors. J Clin Oncol 23:4354–4362PubMedCrossRefGoogle Scholar
  7. 7.
    Shankar AG, Ashley S, Craft AW, Pinkerton CR (2003) Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 40:141–147PubMedCrossRefGoogle Scholar
  8. 8.
    Baum ES, Gaynon P, Greenberg L et al (1981) Phase II trial cisplatin in refractory childhood cancer: Children’s Cancer Study Group Report. Cancer Treat Rep 65(9–10):815–822PubMedGoogle Scholar
  9. 9.
    Balamuth NJ, Womer RB (2010) Ewing’s sarcoma. Lancet Oncol 11(2):184–192PubMedCrossRefGoogle Scholar
  10. 10.
    Hofbauer S, Hamilton G, Theyer G et al (1993) Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing’s sarcoma and peripheral primitive neuroectodermal tumour cell lines. Eur J Cancer 29A(2):241–245PubMedCrossRefGoogle Scholar
  11. 11.
    Planting AS, van der Burg ME, van den Bent MJ et al (1996) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancers. Br J Cancer 73(12):1569–1575PubMedCrossRefGoogle Scholar
  12. 12.
    Planting AS, de Mulder PH, de Graeff A, Verweij J (1997) Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer 33(1):61–65PubMedCrossRefGoogle Scholar
  13. 13.
    Planting AS, van der Burg ME, Goey SH et al (1995) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6(6):613–615PubMedGoogle Scholar
  14. 14.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  15. 15.
    Miller AB, Hoogstraaten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214PubMedCrossRefGoogle Scholar
  16. 16.
    Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS March 1998Google Scholar
  17. 17.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRefGoogle Scholar
  18. 18.
    Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151PubMedCrossRefGoogle Scholar
  19. 19.
    Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing’s Sarcoma (Euro-EWING 99) [NCT00020566]. Accessed 15 July 2012. Available from:
  20. 20.
    Davidson A, Gowing R, Lowis S et al (1997) Phase II study of 21 day schedule oral etoposide in children. New agents group of the United Kingdom Children’s Cancer study group (UKCCSG). Eur J Cancer 33(11):1816–1822PubMedCrossRefGoogle Scholar
  21. 21.
    Jazieh AR, Kyasa MJ, Muirhead MJ (2002) Prolonged administration of infusional cisplatin and oral etoposide in advanced non-small cell lung cancer. Anticancer Drugs 13(8):815–818PubMedCrossRefGoogle Scholar
  22. 22.
    Loehrer PJ, Eihorn LH (1984) Drugs five years later. Cisplatin. Ann Intern Med 100(5):704–713PubMedGoogle Scholar
  23. 23.
    Skinner R, Pearson AD, Coulthard MG et al (1991) Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol 28:81–92PubMedCrossRefGoogle Scholar
  24. 24.
    McHaney VA, Thibadoux G, Hayes FA, Green AA (1983) Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 102(2):314–317PubMedCrossRefGoogle Scholar
  25. 25.
    Brock PR, Bellman SC, Yeomans EC et al (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300PubMedCrossRefGoogle Scholar
  26. 26.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jurgens H (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47(6):795–800PubMedCrossRefGoogle Scholar
  27. 27.
    Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48(2):132–139PubMedCrossRefGoogle Scholar
  28. 28.
    Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP et al (2009) Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 53(6):1029–1034PubMedCrossRefGoogle Scholar
  29. 29.
    Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D et al (2012) Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17(3):e321–e329CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Cormac Owens
    • 1
  • Valerie Laurence
    • 5
  • Lofti Benboubker
    • 6
  • Anne-Sophie Defachelles
    • 7
  • Didier Cupissol
    • 8
  • Hervé Rubie
    • 10
  • Hervé Brisse
    • 4
  • Annie Rey
    • 2
  • Liliane Ollivier
    • 4
  • Dominique Couanet
    • 3
  • Christiane Baunin
    • 9
  • Céline Mahier Aït-Oukhatar
    • 11
  • Odile Oberlin
    • 1
  1. 1.Department of Paediatric OncologyInstitut Gustave RoussyVillejuifFrance
  2. 2.Department of BiostatisticsInstitut Gustave RoussyVillejuifFrance
  3. 3.Department of RadiologyInstitut Gustave RoussyVillejuifFrance
  4. 4.Department of RadiologyInstitut CurieParisFrance
  5. 5.Department of Medical OncologyInstitut CurieParisFrance
  6. 6.Department of Medical OncologyCentre hospitalo-universitaire BretonneauToursFrance
  7. 7.Department of General OncologyCentre Oscar LambretLilleFrance
  8. 8.Department of Medical OncologyCentre Val d’Aurelle Paul LamarqueMontpellierFrance
  9. 9.Department of RadiologyCentre hospitalo-universitaire PurpanToulouseFrance
  10. 10.Department of Paediatric OncologyCentre hospitalo-universitaire PurpanToulouseFrance
  11. 11.Fédération Nationale des Centres Lutte Contre le CancerParisFrance

Personalised recommendations